Advent Pharmaceuticals is a company specialising in the development of novel respiratory technologies. The company plans to commercialise a range of pulmonary delivered therapies for lung and systemic diseases.
Ambri Ltd (ASX code:ABI) developed Ion Channel Switch (ICS) technology as basis for new biosensor products. Company is emerging as a revenue and profit generating business seeking partnership/licensing deal of its biosensor technology.
Biocomm is Australia's pre-eminent life sciences technology management and commercial development company.
CNSBio is a clinical stage company developing combination therapies by combining and repositioning marketed drugs and drugs in late stage clinical development. The lead products are for the treatment of neuropathic pain and inflammatory pain.
www.cnsbio.com
Columna is focused on the next generation of minimally invasive non-fusion spinal implants, a segment expected to represent 70% of the worldwide spine market.
www.columna.com.au
Gelesis Inc is a biopharmaceutical company developing biomaterials and device solutions for treatment of obesity and other related conditions.
Genera Biosystems is a development phase company that designs, develops and produces innovative and clinically effective human molecular diagnostics with a focus on women's health.
www.generabiosystems.com
Hatchtech is dedicated to developing a new generation of low-toxicity insecticides for controlling ectoparasites. The Company has developed a select group of compounds that are highly effective at inhibiting lice eggs from hatching. Hatchtech is initially focussed on developing compounds for controlling human head lice.
www.hatchtech.com.au
Protagonist develops novel classes of therapeutic agents, including small molecules and peptides that are addressing some of the world’s most critical health care needs, such as asthma, rheumatoid and psoriatic arthritis, gastro-intestinal disorders and diabetes-related conditions.
Satori Pharmaceuticals is a biopharmaceutical company developing drugs to treat protein ‘misfolding’ diseases including the two leading causes of neurodegeneration, Alzheimer's disease (AD) and Parkinson's disease (PD).
Telesso Technologies (ASX code: TEO) aims to build company value and shareholder wealth by using capabilites to identify, in-license and develop innovative healthcare solutions.
Tokai Pharmaceuticals is a specialty pharmaceutical company focused on developing drugs for endocrine and paracrine based diseases and conditions.
www.tokaipharmaceuticals.com
Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies to treat metabolic diseases (formerly Adipogen).
Xbio Systems has developed the Integrated Drug Development Platform (IDDP), a unique solution that supports drug and device development by combining process automation, content management and business intelligence capabilities on a secure, adaptable web platform.
Xenome focuses on the discovery and development of peptide pharmaceuticals based on proprietary libraries of venom and related peptides.